CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that ASCO has published an abstract regarding its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The full results will be presented in a poster discussion session at the ASCO 2011 Annual Meeting being held June 3 – 7 in Chicago.
